CAPRICOR THERAPEUTICS, INC. - 8-K Filing
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee is scheduled to meet on July 29, 2026, to discuss Capricor Therapeutics' Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy. The BLA remains on track with an August 22, 2026 PDUFA target action date.
Tickers: $CAPR